Competing Interests
This page lists 303 references in the Main Healthy Skepticism Library relevant to competing interests.
Click on the HSL (Health Skepticism Library) number for more details which may include an abstract or full text.
HSL6828
Finkelstein JB.
FDA revamps committee conflict-of-interest rules.
J Natl Cancer Inst 2006 Oct 4;98(19):1354-5
http://jncicancerspectrum.oxfordjournals.org/cgi/content/full/jnci;98/19/1354
HSL6790
Kaiser J.
Bioethics. Researchers attack newspaper probe of trials.
Science 2006 Sep 22;313(5794):1714
http://www.sciencemag.org/cgi/content/full/313/5794/1714b
HSL6789
Reseland S.
[Stated conflict of interest].
Tidsskr Nor Laegeforen 2006 Sep 21;126(18):2408
http://www.tidsskriftet.no/pls/lts/pa_lt.visSeksjon?vp_SEKS_ID=1429824
HSL6883
Johnston BC, Vohra S.
Investigator-initiated trials are more impartial.
Nature 2006 Sep 14;443(7108):144
http://www.nature.com/doifinder/10.1038/443144a
HSL6799
Freedman R, Lewis DA, Michels R, Pine DS, Schultz SK, Tamminga C, Patterson SL, McIntyre JS, Goldman HH, Yudofsky SC, Hales RE, Rapaport MH, Hales D, Krajeski J, Kupfer DJ, Badaracco MA, Scully JH Jr.
Conflict of interest, round 2.
Am J Psychiatry 2006 Sep 01;163(9):1481-3
http://ajp.psychiatryonline.org/cgi/content/full/163/9/1481
HSL6517
Tanne J.
JAMA's editor stresses authors' need to disclose financial ties.
BMJ 2006 Aug 19;333(7564):370
http://bmj.bmjjournals.com/cgi/content/short/333/7564/370-c?etoc%3e
HSL6742
Taylor M.
Are hospitals next in line? Government investigators probing relationships between physicians, devicemakers may soon train sights on hospitals.
Mod Healthc 2006 Aug 14;36(32):24-6
HSL6747
Vermeulen M.
[Sponsoring of research by the industry is not good for science].
Ned Tijdschr Geneeskd 2006 Aug 12;150(32):1769
HSL6748
Raaijmakers JA.
[Research sponsored by the industry benefits scientific progress].
Ned Tijdschr Geneeskd 2006 Aug 12;150(32):1768
HSL6691
Kormeset PO.
[Written drug advertisements].
Tidsskr Nor Laegeforen 2006 Aug 10;126(15):1946
http://www.tidsskriftet.no/pls/lts/pa_lt.visSeksjon?vp_SEKS_ID=1407848
HSL6692
Asboll E.
[Expert statements concerning the Seroxat issue].
Tidsskr Nor Laegeforen 2006 Aug 10;126(15):1945
http://www.tidsskriftet.no/pls/lts/pa_lt.visSeksjon?vp_SEKS_ID=1407688
HSL6319
Charatan F.
US journal in row over sponsored supplement
BMJ 2006 Aug 5;333(7562):277
http://bmj.bmjjournals.com/cgi/content/short/333/7562/277-a?etoc%3e
HSL6842
Federman DG.
Pens, trips, and the public trust: support for stronger action.
Conn Med 2006 Aug 01;70(7):449-50
HSL6110
Smith R.
Lapses at the New England Journal of Medicine
Journal of the royal society of medicine 2006 Aug 1;99
http://www.rsmpress.co.uk/0607JRSMSmith.pdf
HSL6706
Baxter P.
Medicine and the pharmaceutical industry.
Dev Med Child Neurol 2006 Aug 01;48(8):627
http://journals.cambridge.org/action/displayAbstract?fromPage=online&aid=453299
HSL6201
Roehr B.
US national academies’ panellists are accused of financial conflicts
BMJ 2006 Jul 29;333(7561):219
http://bmj.bmjjournals.com/cgi/content/short/333/7561/219-a?etoc%3e
HSL6143
Mansfield PR.
Another way to tame the monster
BMJ 2006 Jul 22;333(7560):202
http://bmj.bmjjournals.com/cgi/content/short/333/7560/202-a?etoc%3e
HSL6123
Dobson R.
NEJM “failed its readers” by delay in publishing its concerns about VIGOR trial
BMJ 2006 Jul 15;333(7559):116
http://bmj.bmjjournals.com/cgi/content/short/333/7559/116-f?etoc
HSL6149
Kondro W.
Conflicts cause FDA to review advisory committees.
CMAJ 2006 Jul 4;175(1):23
http://www.cmaj.ca/cgi/content/full/175/1/23
HSL6151
Rigby N.
Obesity association clarifies definitions of obesity and links with drug firms.
BMJ 2006 Jul 1;333(7557):44
http://bmj.bmjjournals.com/cgi/content/full/333/7557/44
HSL6153
Jack A.
Too close for comfort?
BMJ 2006 Jul 1;333(7557):13
http://bmj.bmjjournals.com/cgi/content/full/333/7557/13
HSL6984
Standridge JB.
Of doctor conventions and drug companies.
Fam Med 2006 Jul-Aug 01;38(7):518-20
http://www.stfm.org/fmhub/fm2006/July/John518.pdf
HSL6156
Angell M.
Academic medical centers and conflicts of interest.
JAMA 2006 Jun 28;295(24):2848
http://jama.ama-assn.org/cgi/content/full/295/24/2848-a
HSL6157
Watson PY, Musial JL, Khandewal AK, Buckley JD.
Academic medical centers and conflicts of interest.
JAMA 2006 Jun 28;295(24):2847-8
http://jama.ama-assn.org/cgi/content/full/295/24/2847
HSL6158
Ting JY.
Academic medical centers and conflicts of interest.
JAMA 2006 Jun 28;295(24):2846
http://jama.ama-assn.org/cgi/content/full/295/24/2846
HSL6159
Poses RM, Silverstein S, Smith WR.
Academic medical centers and conflicts of interest.
JAMA 2006 Jun 28;295(24):2846-7
http://jama.ama-assn.org/cgi/content/full/295/24/2846-a
HSL6160
Meador KJ.
Academic medical centers and conflicts of interest.
JAMA 2006 Jun 28;295(24):2845
http://jama.ama-assn.org/cgi/content/full/295/24/2845
HSL6161
Gozum ME.
Academic medical centers and conflicts of interest.
JAMA 2006 Jun 28;295(24):2845
http://jama.ama-assn.org/cgi/content/full/295/24/2845-a
HSL6162
Goldblum OM, Franzblau MJ.
Academic medical centers and conflicts of interest.
JAMA 2006 Jun 28;295(24):2845-6
http://jama.ama-assn.org/cgi/content/full/295/24/2845-b
HSL6216
Gotzsche PC, Hrobjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW.
[Constraints on publication rights in industry-initiated clinical trials--secondary publication].
Ugeskr Laeger 2006 Jun 19;168(25):2467-9
HSL5726
Lexchin J, Light DW.
Commercial influence and the content of medical journals.
BMJ 2006 Jun 17;332(7555):1444-7
http://bmj.bmjjournals.com/cgi/content/short/332/7555/1444?etoc
HSL5727
Collier J.
The price of independence.
BMJ 2006 Jun 17;332(7555):1447-9
http://bmj.bmjjournals.com/cgi/content/short/332/7555/1447?etoc
HSL6551
Weiss R.
'Serious misconduct' by NIH expert found: scientist did not report sending tissues to drug firm and getting paid, report says.
Washington Post 2006 Jun 14:A6
HSL6100
Mantone J.
Making research pay. Reaping rewards, conflicts for developing drugs.
Mod Healthc 2006 Jun 12;36(24):17-8
HSL6325
Montgomery JH.
Industry funding and author-industry affiliation in clinical trials in psychiatry.
Am J Psychiatry 2006 Jun 01;163(6):1110-1
http://ajp.psychiatryonline.org/cgi/content/full/163/6/1110
HSL6392
Wilson S.
In defense of full disclosure.
JAAPA 2006 Jun 01;19(6):48-9
HSL6394
Smith R.
Conflicts of interest: how money clouds objectivity.
J R Soc Med 2006 Jun 01;99(6):292-7
http://www.jrsm.org/cgi/content/full/99/6/292http://
HSL6396
Pauls MA, Ackroyd-Stolarz S.
Identifying bioethics learning needs: a survey of Canadian emergency medicine residents.
Acad Emerg Med 2006 Jun 01;13(6):645-52
http://www.aemj.org/cgi/content/full/13/6/645
HSL6625
Rapoport AM.
More on conflict of interest from a clinical professor of neurology in private practice at a headache center.
Headache 2006 Jun 01;46(6):1020-1
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1526-4610.2006.00474_2.x
HSL5489
Spence D.
Research for profit.
BMJ 2006 May 13;332(7550):1155-1156
http://bmj.bmjjournals.com/cgi/content/full/332/7550/1155-c
HSL5478
Mira AJ, Isely W, McDonnell M, Huch KM, Whittle HM, Nugent TJ, Lack DZ
Readers' Responses to "Physicians on the Take"
MedGenMed 2006 May 12
http://www.medscape.com/viewarticle/531612?src=mp
HSL5750
Mackie JE, Taylor AD, Finegold DL, Daar AS, Singer PA.
Lessons on ethical decision making from the bioscience industry.
PLoS Med 2006 May 01;3(5):e129
http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0030129
HSL6326
Jayaraman J.
Whose pen is in your pocket?
Can Fam Physician 2006 May 01;52:586
HSL5566
Carey B.
Study cites links to firms by psychiatrists.
NY Times (Print) 2006 Apr 20;:A23
HSL5648
Lewis DA, Michels R, Pine DS, Schultz SK, Tamminga CA, Freedman R.
Conflict of interest.
Am J Psychiatry 2006 Apr;163(4):571-3
http://ajp.psychiatryonline.org/cgi/pmidlookup?view=long&pmid=16585427
HSL5373
Tandberg A.
[Independent research is important].
Tidsskr Nor Laegeforen 2006 Mar 23;126(7):935-6
http://www.tidsskriftet.no/pls/lts/pa_lt.visSeksjon?vp_SEKS_ID=1362332
HSL4331
Tesoriero H.
Vioxx Doctors Wooed by Merck Are Now Its Foes
The wall street journal 2006 Mar 10
http://online.wsj.com/article/SB114195740527094405.html
HSL5032
Hilliard T, Chambers T.
The relationship between paediatricians and commerce.
Paediatr Respir Rev 2006 Mar;7(1):54-9
http://linkinghub.elsevier.com/retrieve/pii/S1526-0542(05)00086-2
HSL5505
Smith R.
The trouble with medical journals.
J R Soc Med 2006 Mar 01;99(3):115-9
http://www.jrsm.org/cgi/content/full/99/3/115
HSL5508
Leather DA, Davis SC.
Paediatricians and the pharmaceutical industry: an industry perspective of the challenges ahead.
Paediatr Respir Rev 2006 Mar 01;7(1):60-6
http://linkinghub.elsevier.com/retrieve/pii/S1526-0542(05)00117-X
HSL5660
Engelman K.
Rx: professional integrity (prn).
J Clin Hypertens (Greenwich) 2006 Mar 01;8(3):232
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3351&uid=16578956&db=PubMed&url=http://www.lejacq.com/articleDetail.cfm?pid=JClinHypertens_8;3:232
HSL5687
Levin PJ, McGee G.
Physician, divest thyself.
Am J Bioeth 2006 Mar-Apr 01;6(2):1-2
http://taylorandfrancis.metapress.com/(xejiig55vu0ome45n4xojl45)/app/home/contribution.asp?referrer=parent&backto=issue,1,44;journal,2,25;linkingpublicationresults,1:111605,1
HSL6645
DeSilets LD.
Commercial support for professional development.
J Contin Educ Nurs 2006 Mar-Apr 01;37(2):52-3
HSL5431
Coleman DL, Kazdin AE, Miller LA, Morrow JS, Udelsman R.
Guidelines for interactions between clinical faculty and the pharmaceutical industry: one medical school's approach.
Acad Med 2006 Feb 01;81(2):154-60
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3159&uid=16436576&db=PubMed&url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=1040-2446&volume=81&issue=2&spage=154
HSL5755
McCarter G.
Should industry speak the loudest in informing the public on medical matters?
PLoS Med 2006 Feb 01;3(2):e118
http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0030118
HSL6339
Lazarus A.
Pharmaceutical policy issues for medical schools.
Psychiatr Serv 2006 Feb 01;57(2):167
http://ps.psychiatryonline.org/cgi/content/full/57/2/167
HSL5567
Roggla G, Moser B.
Re: Bioethics, the Surviving Sepsis Campaign, and the industry.
Wien Klin Wochenschr 2006 Feb;118(1-2):65
HSL5568
Ricevuti G, Gasparetto C.
Re: Bioethics, the Surviving Sepsis Campaign, and the industry.
Wien Klin Wochenschr 2006 Feb;118(1-2):64-5
HSL5569
Mackenzie AF.
Re: Bioethics, the Surviving Sepsis Campaign, and the industry.
Wien Klin Wochenschr 2006 Feb;118(1-2):64
HSL5570
Malliani A.
Re: Bioethics, the Surviving Sepsis Campaign, and the industry.
Wien Klin Wochenschr 2006 Feb;118(1-2):63-4
HSL5572
Bion J, Vincent JL, Angood P.
Bioethics, the Surviving Sepsis Campaign and the industry.
Wien Klin Wochenschr 2006 Feb;118(1-2):63
HSL5260
Laupacis A.
On bias and transparency in the development of influential recommendations.
CMAJ 2006 Jan 31;174(3):335-6
http://www.cmaj.ca/cgi/pmidlookup?view=long&pmid=16446476
HSL5274
Romano M.
Fighting graft--it's academic. Medical centers must embrace conflict rules: critics.
Mod Healthc 2006 Jan 30;36(5):8-10
HSL5272
Jarhult B.
[Let the profit from drug advertisement in Lakartidningen go to a research foundation!].
Lakartidningen 2006 Jan 25-31;103(4):226
HSL6400
Goodman RL, Carrasquillo O.
The corporate co-author, the ghostwriter, and the medical society: an object lesson (June, 2005 issue).
J Gen Intern Med 2006 Jan 01;21(1):102
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1525-1497.2005.00271_3.x
HSL5207
Flynn G.
The NIH ethics crackdown: a message to the research community.
Ann Emerg Med 2006 Jan;47(1):57-60
HSL5385
Marnell T.
A big issue?
Br J Gen Pract 2006 Jan;56(522):57
http://www.ingentaconnect.com/content/rcgp/bjgp/2006/00000056/00000522/art00011?token=004c17f309b4e7268293c62207d673f582f6b6d383a4b3b257b507b6d7a416a387c6b4654276
HSL5601
Almirall N.
The ethics of engagement with the pharmaceutical industry.
Mich Med 2006 Jan-Feb;105(1):10-2
HSL5606
Breen KJ, Rogers W.
Physicians and the pharmaceutical industry.
Intern Med J 2006 Jan;36(1):66-7
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1445-5994.2005.00993.x
HSL6562
Dresser R.
Private-sector research ethics: marketing or good conflicts management The 2005 John J. Conley Lecture on Medical Ethics
Theor Med Bioeth. 2006;27(2):115-39 2006;27(2):115-39
http://www.springerlink.com/content/bq855531108k52p6/
HSL6810
Cosgrove L, Krimsky S, Vijayaraghavan M, Schneider L.
Financial ties between DSM-IV panel members and the pharmaceutical industry.
Psychother Psychosom 2006;75(3):154-60
http://content.karger.com/produktedb/produkte.asp?typ=fulltext&file=PPS2006075003154
HSL5301
Thomas PS, Tan KS, Yates DH.
Ethical issues in the relationships involving medicine and industry.
Intern Med J 2005 Dec;35(12):732
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3046&uid=16313554&db=PubMed&url=http://www.blackwell-synergy.com/openurl?genre=article&sid=nlm:pubmed&issn=1444-0903&date=2005&volume=35&issue=12&spage=732
HSL5354
Cherry MJ.
The market and medical innovation: human passions and medical advancement.
J Med Philos 2005 Dec;30(6):555-69
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3396&uid=16396784&db=PubMed&url=http://taylorandfrancis.metapress.com/openurl.asp?genre=article&issn=0360-5310&volume=30&issue=6&spage=555
HSL5041
Halperin SA, Scheifele D, Duval B, Ward B.
Conforming to ICMJE principles.
CMAJ 2005 Nov 22;173(11):1358-9
http://www.cmaj.ca/cgi/content/full/173/11/1358-c
HSL5042
Lexchin J.
A hypertensive snow bird.
CMAJ 2005 Nov 22;173(11):1357
http://www.cmaj.ca/cgi/content/full/173/11/1357-a
HSL5043
Marlow B.
A hypertensive snow bird.
CMAJ 2005 Nov 22;173(11):1357-8
http://www.cmaj.ca/cgi/content/full/173/11/1357-b
HSL5045
Clinical practice guidelines and conflict of interest.
CMAJ 2005 Nov 22;173(11):1297,
http://www.cmaj.ca/cgi/content/full/173/11/1297
HSL5052
Catton M.
Medical schools tackle conflict of interest.
CMAJ 2005 Nov 8;173(10):1143
HSL5262
Komesaroff PA.
Ethical issues in the relationships with industry: an ongoing challenge. New Guidelines open for public comment.
J Paediatr Child Health 2005 Nov;41(11):558-60
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1440-1754.2005.00719.x
HSL5296
McHenry L.
On the origin of great ideas: science in the age of big pharma.
Hastings Cent Rep 2005 Nov-Dec;35(6):17-9
HSL5330
Prat EH.
[Is the pharmaceutical industry really as bad as its reputation?]
Wien Med Wochenschr 2005 Nov;155(21-22):502-12
HSL3744
Tanne JH.
Doctors who write guidelines often have ties to the drug industry
BMJ 2005 Oct 29;331:982
http://bmj.bmjjournals.com/cgi/content/full/331/7523/982-a
HSL5059
Blackledge GR.
The difficulties industry is facing with investigators.
Eur J Cancer 2005 Oct 01;41(15):2210-2
http://linkinghub.elsevier.com/retrieve/pii/S0959-8049(04)00985-2
HSL5062
Nardone DA.
Doctors and the drug industry: reader feedback.
Am J Med 2005 Oct;118(10):1176-7
http://linkinghub.elsevier.com/retrieve/pii/S0002-9343(05)00202-0
HSL5063
Warrier R, Houghton B.
Doctors and the drug industry: reader feedback.
Am J Med 2005 Oct;118(10):1175-6
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3048&uid=16194656&db=PubMed&url=http://linkinghub.elsevier.com/retrieve/pii/S0002-9343(05)00277-9
HSL5608
Benedetti L.
We must find the problem in the intrinsic mechanisms of both media and medical research.
PLoS Med 2005 Oct;2(10):e364
http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0020364
HSL5078
Banks D.
Pharmacists, pharmaceutical manufacturers, and conflicts of interest.
Am J Health Syst Pharm 2005 Sep 1;62(17):1827-32
http://www.ajhp.org/cgi/content/full/62/17/1827
HSL5254
Mahowald MW, Cramer Bornemann MA.
What? Influenced by industry? Not me!
Sleep Med. 2005 Sep 01;6(5):389-90
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3048&uid=16099216&db=pubmed&url=http://linkinghub.elsevier.com/retrieve/pii/S1389-9457(05)00109-7
HSL5268
Schwartz B.
Receiving gifts: a conflict of interest discussion.
J Can Dent Assoc 2005 Sep;71(8):561-2
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3166&uid=16202193&db=PubMed&url=http://www.cda-adc.ca/jcda/vol-71/issue-8/561.html
HSL5280
Lazarus A.
Individual wariness needed to spot biased drug research.
Manag Care 2005 Sep;14(9):8,
HSL4173
Hotvedt R.
Drug companies and continuing education.
Tidsskr Nor Laegeforen 2005 Aug 11;125(15):2043
http://www.tidsskriftet.no/pls/lts/pa_lt.visSeksjon?vp_SEKS_ID=1237547
HSL4215
Guomundsson S.
Doctors and drug companies: the beauty and the beast?
Acta Ophthalmol Scand 2005 Aug 01;83(4):407-8
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3046&uid=16029261&db=pubmed&url=http://www.blackwell-synergy.com/openurl?genre=article&sid=nlm:pubmed&issn=1395-3907&date=2005&volume=83&issue=4&spage=407
HSL6765
Duval G.
The benefits and threats of research partnerships with industry.
Crit Care 2005 Aug 01;9(4):309-10
http://ccforum.com/content/9/4/309
HSL4200
Engelhardt K.
[The medical-industrial complex: an ethical challenge]
Dtsch Med Wochenschr. 2005 Jul 29;130(30):1778-80
http://www.thieme-connect.com/DOI/DOI?10.1055/s-2005-871895
HSL2485
Ruff TA, Haikal-Mukhtar H.
Doctors, drugs, information and ethics: a never-ending story.
Med J Aust 2005 Jul 18;183(2):73-4
http://www.mja.com.au/public/issues/183_02_180705/ruf10450_fm.html
HSL1997
Elliott C.
Should journals publish industry-funded bioethics articles?
The Lancet 2005 Jul 6;366
http://www.thelancet.com/journals/lancet/article/PIIS0140673605667943/fulltext
HSL5761
Wager E, Jacobs A.
Response to 'the corporate coauthor'.
J Gen Intern Med 2005 Jul 01;20(7):672
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1525-1497.2005.051181.x
HSL6401
Cohen D.
Bold suggestion by Smith.
PLoS Med 2005 Jul 01;2(7):e226
http://www.pubmedcentral.gov/articlerender.fcgi?tool=pubmed&pubmedid=16033320
HSL6402
Sheldon T.
Focus on the funding and production of evidence rather than its publication.
PLoS Med 2005 Jul 01;2(7):e222
http://www.pubmedcentral.gov/articlerender.fcgi?tool=pubmed&pubmedid=16033316
HSL6403
Marcovitch H.
Little fish are less likely to take the bait.
PLoS Med 2005 Jul 01;2(7):e221
http://www.pubmedcentral.gov/articlerender.fcgi?tool=pubmed&pubmedid=16033315
HSL6405
Senn S.
Bitter pills and puffed trials.
PLoS Med 2005 Jul 01;2(7):e219
http://www.pubmedcentral.gov/articlerender.fcgi?tool=pubmed&pubmedid=16033313
HSL6406
Frighi V.
Medical journals, academia, and industry-sponsored clinical trials.
PLoS Med 2005 Jul 01;2(7):e218
http://www.pubmedcentral.gov/articlerender.fcgi?tool=pubmed&pubmedid=16033312
HSL1916
Rowland C.
Doctors fight over drug firm influence: Some in hypertension society hit fees paid to members for talks
The Boston Globe 2005 Jun 16
HSL1909
Berenson A.
At Pfizer, the Isolation Increases for a Whistle-Blower: No man is an island. But Peter Rost is getting close.
2005 Jun 8
HSL2388
Henry DA, Kerridge IH, Hill SR, McNeill PM, Doran E, Newby DA, Henderson KM, Maguire J, Stokes BJ, Macdonald GJ, Day RO.
Medical specialists and pharmaceutical industry-sponsored research: a survey of the Australian experience.
Med J Aust 2005 Jun 6;182(11):557-60
http://www.mja.com.au/public/issues/182_11_060605/hen10805_fm.html
HSL2496
Lindberg M.
[When will we see "Physicians without sponsors" in Sweden?]
Lakartidningen 2005 Jun 6-12;102(23):1830
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15997555&query_hl=8
HSL4225
Timimi S.
Psychiatry has effectively become a commodity that is being sold to the drug industry.
Ment Health Today 2005 Jun 01;:21
HSL4235
Fineberg HV.
Reply to "Can the Institute of Medicine review the FDA?".
Nat Med 2005 Jun;11(6):589. 2005 Jun 01;11(6):589
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3094&uid=15937463&db=pubmed&url=http://dx.doi.org/10.1038/nm0605-589a
HSL5039
Rasmussen LM.
The ethics and aesthetics of for-profit bioethics consultation.
HEC Forum 2005 Jun;17(2):94-121
HSL1873
Zimmerman R, Tomsho R.
Medical Editor Turns Activist On Drug Trials
The Wall Street Journal 2005 May 26
HSL1834
Silverman E.
Biz Buzz: Actress's on-screen personalities collide at conference
New Jersey Star Ledger 2005 May 11
HSL5511
Smith R.
Medical journals are an extension of the marketing arm of pharmaceutical companies.
PLoS Med 2005 May 01;2(5):e138
http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0020138
HSL5358
Sociedades Medicas-Cientificas miembros de la Asociacion de Sociedades Cientificas-Medicas de Chile.
[Recommendations to avoid conflicts of interest].
Rev Med Chil 2005 May;133(5):607-8
http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872005000500015&lng=en&nrm=iso
HSL4255
Komesaroff P.
Ethical issues in the relationships involving medicine and industry: evolving problems require evolving.
Intern Med J 2005 Apr 01;35(4):203-5
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3046&uid=15836496&db=pubmed&url=http://www.blackwell-synergy.com/openurl?genre=article&sid=nlm:pubmed&issn=1444-0903&date=2005&volume=35&issue=4&spage=203
HSL2387
Kerridge I, Maguire J, Newby D, McNeill PM, Henry D, Hill S, Day R, Macdonald G, Stokes B, Henderson K.
Cooperative partnerships or conflict-of-interest? A national survey of interaction between the pharmaceutical industry and medical organizations.
Intern Med J 2005 Apr;35(4):206-10
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1444-0903.2004.00799.x
HSL2142
Watson PY, Khandelwal AK, Musial JL, Buckley JD.
Resident and faculty perceptions of conflict of interest in medical education.
J Gen Intern Med 2005 Apr;20(4):357-9
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1525-1497.2005.04075.x
HSL5469
How does PLoS medicine manage competing interests?
PLoS Med 2005 Mar 01;2(3):e88
http://www.pubmedcentral.gov/articlerender.fcgi?tool=pubmed&pubmedid=15783268
HSL5088
Mather C.
The pipeline and the porcupine: alternate metaphors of the physician-industry relationship.
Soc Sci Med 2005 Mar;60(6):1323-34
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VBF-4D5JSJJ-2&_coverDate=03%2F01%2F2005&_alid=398122182&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=5925&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=a3b4c00f922432b53675cfc8e056c2cd
HSL5969
Steinbrook R.
Commercial support and continuing medical education.
N Engl J Med 2005 Feb 10;352(6):534-5
http://content.nejm.org/cgi/content/extract/352/6/534
HSL1931
Mohl PC.
Psychiatric training program engagement with the pharmaceutical industry: an educational issue, not strictly an ethical one.
Acad Psychiatry 2005 Sum;29(2):215-21
http://ap.psychiatryonline.org/cgi/content/full/29/2/215
HSL5084
Kahn JP.
Lessons in conflict of interest: the construction of the martyrdom of David Healy and the dilemma of bioethics.
Am J Bioeth 2005 Sum;5(3):W13
http://taylorandfrancis.metapress.com/(iiz3n4n1mkazbl45vc3o1i45)/app/home/contribution.asp?referrer=parent&backto=issue,31,34;journal,6,24;linkingpublicationresults,1:111605,1
HSL5085
Elliott C.
Lessons in conflict of interest: the construction of the martyrdom of David Healy and the dilemma of bioethics.
Am J Bioeth 2005 Summer;5(3)
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3396&uid=16006354&db=PubMed&url=http://taylorandfrancis.metapress.com/openurl.asp?genre=article&issn=1526-5161&volume=5&issue=3&spage=W16
HSL5201
Cain DM, Loewenstein G, Moore DA.
The Dirt on Coming Clean: Perverse Effects of Disclosing Conflicts of Interest
The Journal of Legal Studies 2005;34:1-25
http://www.journals.uchicago.edu/cgi-bin/resolve?id=doi:10.1086/426699&erFro&erFrom=-5865837686719988574Guest
HSL5336
Klanica K.
Conflicts of interest in medical research: how much conflict should exceed legal boundaries?
J Biolaw Bus 2005;8(3):37-45
HSL5345
Polonuer JL.
[Strategies for drug promotion].
Medicina (B Aires) 2005;65(4):373-6
HSL5427
Caulfield T.
Commentary: an independent voice?: conflicts of interest and research on ethical, legal and social issues.
Health Law Rev 2005;13(2-3):114-6
HSL5428
Caulfield T.
Legal and ethical issues associated with patient recruitment in clinical trials: the case of competitive enrolment.
Health Law Rev 2005;13(2-3):58-61
HSL5507
Mastai R.
[Clinical practice and pharmaceutical industry: an always difficult relationship].
Acta Gastroenterol Latinoam 2005;35(4):209-10
HSL1922
Offerhaus L.
[The pharmaceutical industry in scandal: Mercury or Aesculapius?]
Ned Tijdschr Geneeskd 2004 Dec 18;148(51):2554-6
HSL5874
Fontanarosa PB, Rennie D, DeAngelis CD.
Postmarketing surveillance--lack of vigilance, lack of trust.
JAMA 2004 Dec 1;292(21):2647-50
http://jama.ama-assn.org/cgi/content/full/292/21/2647
HSL2095
Abraham J.
Pharmaceuticals, the state and the global harmonisation process.
Aust Health Rev 2004 Nov 8;28(2):150-60
http://www.aushealthreview.com.au/publications/articles/issues/ahr_28_2_081104/ahr_28_2_150-160.asp
HSL5393
Moynihan R.
The intangible magic of celebrity marketing.
PLoS Med 2004 Nov;1(2):e42
http://www.pubmedcentral.gov/articlerender.fcgi?tool=pubmed&pubmedid=15578110
HSL2808
Lachin JM.
Conflicts of interest in data monitoring of industry versus publicly financed clinical trials.
Stat Med 2004 May 30;23(10):1519-21
http://www3.interscience.wiley.com/cgi-bin/abstract/108561304/ABSTRACT
HSL2807
Helft PR, Ratain MJ, Epstein RA, Siegler M.
Inside information: Financial conflicts of interest for research subjects in early phase clinical trials.
J Natl Cancer Inst 2004 May 5;96(9):656-61
http://jncicancerspectrum.oxfordjournals.org/cgi/content/full/jnci;96/9/656
HSL257
Rogers WA, Mansfield PR, Braunack-Mayer AJ, Jureidini JN.
The ethics of pharmaceutical industry relationships with medical students.
Med J Aust 2004 Apr 19;180(8):411-4
http://www.mja.com.au/public/issues/180_08_190404/rog10715_fm.html
HSL2083
Breen KJ.
The medical profession and the pharmaceutical industry: when will we open our eyes?
Med J Aust 2004 Apr 19;180(8):409-10
http://www.mja.com.au/public/issues/180_08_190404/bre10055_fm.html
HSL2379
Schroter S, Morris J, Chaudhry S, Smith R, Barratt H.
Does the type of competing interest statement affect readers' perceptions of the credibility of research? Randomised trial.
BMJ 2004 Mar 27;328(7442):742-3
http://www.pubmedcentral.gov/articlerender.fcgi?tool=pubmed&pubmedid=14980983
HSL671
Schafer A.
Biomedical conflicts of interest: a defence of the sequestration thesis-learning from the cases of Nancy Olivieri and David Healy.
J Med Ethics 2004 Feb;30(1):8-24
http://jme.bmjjournals.com/cgi/content/full/30/1/8
HSL2089
Baylis F.
The Olivieri debacle: where were the heroes of bioethics?
J Med Ethics 2004 Feb;30(1):44-9
http://jme.bmjjournals.com/cgi/content/full/30/1/44
HSL2795
Ferris LE, Singer PA, Naylor CD.
Better governance in academic health sciences centres: moving beyond the Olivieri/Apotex Affair in Toronto.
J Med Ethics 2004 Feb;30(1):25-9
http://jme.bmjjournals.com/cgi/content/full/30/1/25
HSL2796
Holmes DR Jr, Firth BG, James A, Winslow R, Hodgson PK, Gamble GL, Popp RL, Harrington RA.
Conflict of interest
Am Heart J 2004 Feb;147(2):228-37
HSL2786
Friedman LS, Richter ED.
Relationship between conflicts of interest and research results.
J Gen Intern Med 2004 Jan;19(1):51-6
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1525-1497.2004.30617.x?cookieSet=1
HSL5211
Bal A.
Can the medical profession and the pharmaceutical industry work ethically for better health care?
Indian J Med Ethics 2004 Jan-Mar;1(1):17
HSL5212
Gulhati CM.
Needed: closer scrutiny of clinical trials.
Indian J Med Ethics 2004 Jan-Mar;1(1):4-5
HSL5213
Roy N.
Who rules the great Indian drug bazaar?
Indian J Med Ethics 2004 Jan-Mar;1(1):2-3
HSL306
McCarthy M.
NIH told to provide records in conflict of interest probe.
Lancet 2003 Dec 20;362(9401):2076
http://www.thelancet.com/journal/vol362/iss9401/abs/llan.362.9401.news.28183.1
HSL1477
Antonuccio DO, Danton WG, McClanahan TM.
Psychology in the prescription era: building a firewall between marketing and science.
Am Psychol 2003 Dec 01;58(12):1028-43
http://content.apa.org/journals/amp/58/12/1028
HSL2227
Rutledge P, Crookes D, McKinstry B, Maxwell SR.
Do doctors rely on pharmaceutical industry funding to attend conferences and do they perceive that this creates a bias in their drug selection? Results from a questionnaire survey.
Pharmacoepidemiol Drug Saf. 2003 Dec 01;12(8):663-7.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=14762982&query_hl=3
HSL6313
Warner TD, Gluck JP.
What do we really know about conflicts of interest in biomedical research?
Psychopharmacology (Berl) 2003 Dec 01;171(1):36-46
http://www.springerlink.com/(13h2cx45krkzla45np3myu45)/app/home/contribution.asp?referrer=parent&backto=issue,6,17;journal,62,719;linkingpublicationresults,1:100390,1
HSL2518
Moynihan R.
Who pays for the pizza? Redefining the relationships between doctors and drug companies. 2: Disentanglement.
BMJ 2003 May 31;326(7400):1193-6
http://bmj.bmjjournals.com/cgi/content/full/326/7400/1193
HSL1428
Jorgensen J, Djurhuus JC.
[Openness in the cooperation between physicians and private corporations]
Ugeskr Laeger. 2003 Apr 14;165(16):1642-5
HSL1451
Derauf , Dd .
Surely you jest?
BMJ 2003 Mar 15;325(7377):1375
http://bmj.com/cgi/eletters/325/7377/1375
HSL1419
Kristiansen IS.
Broadening the concept of competing interests
BMJ 2003 Jan 3;325(7377):1375
http://bmj.com/cgi/eletters/325/7377/1375
HSL2105
Weatherall D.
Problems for biomedical research at the academia-industrial interface.
Sci Eng Ethics 2003 Jan;9(1):43-8
HSL2229
Radinsky G.
The spotlight on PBMs: federal enforcement of the anti-kickback statute on the pharmaceutical benefit management industry.
J Health Law 2003 Spr;36(2):213-46
HSL2236
Motchane JL.
Health for all or riches for some: WHO's responsible?
Int J Health Serv 2003;33(2):395-400
HSL2623
Jureidini J, Mansfield PR.
Avoiding competing interests
BMJ 2002 Dec 27;325(7377):1375
http://bmj.com/cgi/eletters/325/7377/1375
HSL2252
Thorat MA .
Grading the competing interests
BMJ 2002 Dec 20;325(7377):1375
http://bmj.com/cgi/eletters/325/7377/1375
HSL2906
Ashcroft RE.
Conflicts of interest
BMJ 2002 Dec 17;325(7377):1375
http://bmj.com/cgi/eletters/325/7377/1375
HSL2263
Smith R.
Making progress with competing interests.
BMJ 2002 Dec 14;325(7377):1375-6
http://bmj.com/cgi/reprint/325/7377/1375.pdf
HSL2890
Chaudhry S, Schroter S, Smith R, Morris J.
Does declaration of competing interests affect readers' perceptions? A randomised trial.
BMJ 2002 December 14;325:1391-1392
http://bmj.com/cgi/content/full/325/7377/1391
HSL2144
Chakrabarti A, Fleisher WP, Staley D, Calhoun L.
Interactions of staff and residents with pharmaceutical industry: a survey of psychiatric training program policies.
Ann R Coll Physicians Surg Can 2002 Dec;35(8)
HSL2248
Vitry AI, Hurley E.
The road to consensus: considerations for the safe use and prescribing of COX-2-specific inhibitors.
Med J Aust 2002 Nov 18;177(10):572-3
http://www.mja.com.au/public/issues/177_10_181102/vitry_181102.html
HSL2295
Rakatansky H.
Review article: gastroenterology and the pharmaceutical industry.
Aliment Pharmacol Ther 2002 Nov;16(11):1859-66
http://www.blackwell-synergy.com/doi/abs/10.1046/j.1365-2036.2002.01362.x
HSL2856
Transparency International.
Slovak judge, German pharmacologist and Brazilian campaigner win anti-corruption award
2002 Sep 30
http://www.transparency.org/pressreleases_archive/2002/2002.09.30.anti_corruption_award.html
HSL2309
Moynihan R.
Alosetron: a case study in regulatory capture, or a victory for patients' rights?
BMJ 2002 Sep 14;325(7364):592-5
http://bmj.bmjjournals.com/cgi/content/full/325/7364/592
HSL2245
Wall LL, Brown D.
Pharmaceutical sales representatives and the doctor/patient relationship.
Obstet Gynecol 2002 Sep;100(3):594-9
http://www.greenjournal.org/cgi/content/full/100/3/594
HSL2439
Sackett DL.
The arrogance of preventive medicine.
CMAJ 2002 Aug 20;167(4):363-4
http://www.cmaj.ca/cgi/content/full/167/4/363
HSL2287
Shamasunder B, Bero L.
Financial ties and conflicts of interest between pharmaceutical and tobacco companies.
JAMA 2002 Aug 14;288(6):738-44
http://jama.ama-assn.org/cgi/content/full/288/6/738
HSL2620
Kjaergard LL, Als-Nielsen B.
Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ.
BMJ 2002 Aug 3;325(7358):249
http://bmj.com/cgi/content/full/325/7358/249
HSL2617
Klein JE, Fleischman AR.
The private practicing physician-investigator: ethical implications of clinical research in the office setting.
Hastings Cent Rep 2002 Jul-Aug;32(4):22-6
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12362520
HSL2612
Leenen FH.
Conflicts of interest and libel action.
N Engl J Med 2002 Jun 13;346(24):1919-20
HSL2877
Drazen JM, Curfman GD.
Financial associations of authors.
N Engl J Med 2002 Jun 13;346(24):1901-2
http://content.nejm.org/cgi/content/full/346/24/1901
HSL2880
Detsky A[AU].
Dr Detsky replies
NEJM 2002 Jun 13;346(24):1920
HSL2875
The Editor
Just how tainted has medicine become.
Lancet 2002 April 6;359(9313):1167
http://linkinghub.elsevier.com/retrieve/pii/S0140673602081989
HSL5961
Just how tainted has medicine become?
Lancet 2002 Apr 6;359(9313):1167
http://linkinghub.elsevier.com/retrieve/pii/S0140673602081989
HSL114
Lenzer J.
Alteplase for stroke: money and optimistic claims buttress the “brain attack“ campaign.
BMJ 2002 Mar 23;324:723-726
http://bmj.bmjjournals.com/cgi/content/full/324/7339/723
HSL2304
Orellana C.
German doctors' links with drug firm investigated.
Lancet 2002 Mar 23;359(9311):1039
http://linkinghub.elsevier.com/retrieve/pii/S0140673602081126
HSL2262
Spilker B.
The benefits and risks of a pack of M&Ms: A pharmaceutical spokesman answers his industry's critics
Health Affairs 2002 3-4;21(2):243-244
http://content.healthaffairs.org/cgi/reprint/21/2/243?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&author1=Spilker+B&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT
HSL2881
Davidoff F.
Between the lines: Navigating the uncharted territory of industry-sponsored research: A former medical journal editor describes how and why staff changed their policy on disclosing conflicts of interest.
Health Affairs 2002 Mar-Apr;21(2):235-242
HSL2265
Shuchman M.
The Olivieri dispute: no end in sight?
CMAJ 2002 Feb 19;166(4):487
http://www.cmaj.ca/cgi/content/full/166/4/487, http://www.cmaj.ca/cgi/reprint/166/4/487.pdf
HSL2872
Gibson E, Baylis F, Lewis S.
Dances with the pharmaceutical industry.
CMAJ 2002 Feb 19;166(4):448-50
http://www.cmaj.ca/cgi/pmidlookup?view=long&pmid=11873922
HSL2616
Komesaroff PA, Kerridge IH.
Ethical issues concerning the relationships between medical practitioners and the pharmaceutical industry
Med J Aust 2002 Feb 4;176(3):118-21
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11936308
HSL2253
Thomas PS, Tan KS, Yates DH.
Sponsorship, authorship, and accountability.
Lancet 2002 Jan 26;359(9303):351
http://linkinghub.elsevier.com/retrieve/pii/S0140673602075062
HSL2264
Simmer WS.
Just what the doctor ordered: avoiding kickback pitfalls with prescription drugs.
Manag Care Interface 2002 Jan;15(1):90-2
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11828611
HSL2621
Kind M.
[Physicians--victims or promoters of corruption?].
Wien Med Wochenschr. 2002;152(9-10):249-52
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12094402
HSL111
Saver JL, Kidwell CS, Starkman S.
Commentary: thrombolysis in stroke: it works!
BMJ 2002;324:727-729
http://bmj.bmjjournals.com/cgi/content/full/324/7339/723
HSL115
Coyle SL.
Physician-industry relations. Part 2: organizational issues
Ann Intern Med 2002;136:403-406
http://www.annals.org/cgi/reprint/136/5/403.pdf
HSL116
Coyle SL.
Physician-industry relations. Part 1: individual physicians
Ann Intern Med 2002;136:396-401
http://www.annals.org/cgi/reprint/136/5/396.pdf
HSL117
Choudhry NK, Stelfox HT, Detsky AS
Relationships between authors of clinical practice guidelines and the pharmaceutical industry
JAMA 2002;287:612-617
http://jama.ama-assn.org/cgi/content/full/287/5/612
HSL2244
Warlow C.
Commentary: who pays the guideline writers
BMJ 2002;324:726-727
HSL2246
Vlasov VV.
[Emerging problems of medical ethics in Russia: medical practice and research]
Kardiologiia. 2002;42(5):81-4. 2002;42(5):81-4
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12494154&query_hl=7
HSL2307
Neubauer A.
[Consequences of the German anticorruption law for sponsorship at university hospitals].
Wien Med Wochenschr 2002;152(9-10):246-8
http://www.blackwell-synergy.com/doi/abs/10.1046/j.1563-258X.2002.02038.x
HSL2865
Hirsch LJ.
Conflicts of interest in drug development: the practices of Merck & Co., Inc
Sci Eng Ethics 2002 July;8(3):429-42
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12353373
HSL2867
Healy DI.
Conflicting interests in Toronto: anatomy of a controversy at the interface of academia and industry.
Perspect Biol Med 2002 Spr;45(2):250-63
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11919383
HSL2870
Golden GA, Parochka JN, Overstreet KM.
Medical education and communication companies: an updated in-depth profile.
J Contin Educ Health Prof 2002 Win;22(1):55-62
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12004641
HSL2608
Quick J.
Maintaining the integrity of the clinical evidence base
World Health Organisation Bulletin 2001 Dec
HSL2626
Weber LJ, Wayland MT, Holton B.
Health care professionals and industry: reducing conflicts of interest and established best practices.
Arch Phys Med Rehabil 2001 Dec;82(12)
http://linkinghub.elsevier.com/retrieve/pii/aapmr082b0s20
HSL2774
Newsweek 'adverzine'?
Consumers Union 2001 Dec:63
HSL5065
Elliott C.
Pharma buys a conscience.
Am Prospect 2001 Sep-Oct 24;12(17):16-20
HSL2525
Davidoff F, DeAngelis CD, Drazen JM, Hoey J, Hojgaard L, Horton R, Kotzin S, Nicholls MG, Nylenna M, Overbeke AJ, Sox HC, Van Der Weyden MB, Wilkes MS.
Sponsorship, authorship, and accountability.
Lancet 2001 Sep 15;358(9285):854-6
http://linkinghub.elsevier.com/retrieve/pii/S0140673601060354
HSL2637
McCarthy M.
Drug firm support of American Medical Association ethics effort draws fire.
Lancet 2001 Sep 8;358(9284):821
http://linkinghub.elsevier.com/retrieve/pii/S0140673601060214
HSL2678
Silversides , A .
Hospital denies that withdrawal of MD's job offer was related to drug-company funding
Canadian Medical Association Journal 2001 Jun 26;164(13):1879
HSL2167
Marcoux H, Lamontagne C, Cayer S, Desrochers A, Gauthier D.
[The development of ethics. Identifying what training in medical ethics is needed by family physicians]
Can Fam Physician 2001 Jun;47:1208-15
HSL2523
Jackson T.
Are you being duped?
BMJ 2001 May 26;322:1312
http://bmj.bmjjournals.com/cgi/content/full/322/7297/1312
HSL2680
Ramsay S.
Online database reveals researchers' industry ties.
Lancet 2001 May 26;357(9269):1677
http://linkinghub.elsevier.com/retrieve/pii/S0140673600048625
HSL2171
Johnson RG.
Physician education and the pharmaceutical industry.
Chest 2001 Apr;119(4):995-6
http://www.chestjournal.org/cgi/content/full/119/4/995
HSL2757
Lo B, Wolf L .
Conflict-of-interest policies
NEJM 2001 Mar 29;344(13):1018
HSL2758
McCrary , S. V, L B.Brody, B A.
Conflict-of-interest policies
NEJM 2001 Mar 29;344(13):1018
HSL2760
Nurok , M .
Conflict-of-interest policies
NEJM 2001 Mar 29;344(13):1017
HSL2762
Topol , E J.
Conflict-of-interest policies
NEJM 2001 Mar 29;344(13):1017
HSL2918
Topol E.
Conflict-of-interest policies (1st of 6 letters)
New England Journal of Medicine 2001 Mar 29;344(13):1017
HSL2948
Ratain M.
Conflict-of-interest policies (3rd of 6 letters)
New England Journal of Medicine 2001 Mar 29;344(13):1018
HSL2951
Nurok M.
Conflict-of-interest policies (2nd of 6 letters)
New England Journal of Medicine 2001 Mar 29;344(13):1017
HSL2956
Miller F.
To protect those who serve (1st of 2 letters)
New England Journal of Medicine 2001 Mar 29;344(13):1018-9
HSL2963
McCrary SV, McCullough LB, Brody BA.
Conflict-of-interest policies (5th of 6 letters)
New England Journal of Medicine 2001 Mar 29;344(13):1018
HSL2964
Martin J, Kasper D.
Conflict-of-interest policies (6th of 6 letters)
New England Journal of Medicine 2001 Mar 29;344(13):1018
HSL2966
Lo B, Wolf L.
Conflict-of-interest policies (4th of 6 letters)
New England Journal of Medicine 2001 Mar 29;344(13):1018
HSL127
Lewis S, Baird P, Evans RG, Ghali WA, Wright CJ, Gibson E, et al
Dancing with the porcupine: rules for governing the university-industry relationship
Can Med Assoc J 2001;165:783-785
http://www.cmaj.ca/cgi/content/full/165/6/783
HSL345
Lo B, Wolf LE, Berkeley A.
Conflict-of-interest policies for investigators in clinical trials.
N Engl J Med 2000 Nov 30;343(22):1616-20
http://content.nejm.org/cgi/content/abstract/343/22/1616
HSL3049
Martin JB, Kasper DL.
In whose best interest? Breaching the academic-industrial wall
New England Journal of Medicine 2000 November 30;343(22):1646-1649
http://content.nejm.org/cgi/content/extract/343/22/1646
HSL5315
Bhatt AD.
Clinical trial publications.
Issues Med Ethics 2000 Oct-Dec;8(4):119-21
HSL3048
McCarthy M.
Conflict of interest taints vaccine approval process, charges US report.
Lancet 2000 Sep 2;356(9232):838
HSL3014
Recker RR.
Disclosure of authors' conflicts of interest--a follow-up.
N Engl J Med 2000 Jul 13;343(2):146
http://content.nejm.org/cgi/content/full/343/2/146
HSL3030
Recker RR.
Disclosure of authors' conflicts of interest - A follow-up (2nd of 4 letters)
New England Journal of Medicine 2000 Jul 13;343(2):146
http://content.nejm.org/cgi/content/full/343/2/146
HSL3043
McMasters KM.
Disclosure of authors' conflicts of interest - A follow-up (1st of 4 letters)
New England Journal of Medicine 2000 Jul 13;343(2):146
http://content.nejm.org/cgi/content/full/343/2/146
HSL361
Angell M.
Is academic medicine for sale?
N Engl J Med 2000 May 18;342(20):1516-8
http://content.nejm.org/cgi/content/extract/342/20/1516
HSL2987
Weatherall D.
Academia and industry: increasingly uneasy bedfellows.
Lancet 2000 May 6;355(9215):1574
http://linkinghub.elsevier.com/retrieve/pii/S014067360002211X
HSL2516
Wynia MK, Latham SR, Kao AC, Berg JW, Emanuel LL.
Medical professionalism in society.
N Engl J Med 1999 Nov 18;341(21):1612-6
http://content.nejm.org/cgi/content/extract/341/21/1612
HSL322
Vandenbroucke JP, Helmerhorst FM, Rosendaal FR.
Competing interests and controversy about third generation oral contraceptives: BMJ readers should know whose words they read.
BMJ 1999 Sep;319(7213):795-6
http://bmj.bmjjournals.com/cgi/content/full/320/7231/381/a
HSL5247
Ravindran GD.
The physician and the pharmaceutical industry: both must keep the patient's interests at heart.
Issues Med Ethics 1999 Jan-Mar;7(1):21-2
HSL5927
Wood AJ, Stein CM, Woosley R.
Making medicines safer--the need for an independent drug safety board.
N Engl J Med 1998 Dec 17;339(25):1851-4
http://content.nejm.org/cgi/content/extract/339/25/1851
HSL523
Phillips RA, Hoey J.
Constraints of interest: lessons at the Hospital for Sick Children.
CMAJ 1998 Oct 20;159(8):955-7
http://www.cmaj.ca/cgi/reprint/159/8/955
HSL504
A meeting too many.
Lancet 1998 Oct 10;352(9135):1161
http://linkinghub.elsevier.com/retrieve/pii/S0140673698000324
HSL509
Smith R.
Beyond conflict of interest: Transparency is the key.
BMJ. 1998 Aug 1;317(7154):291-2
http://bmj.bmjjournals.com/cgi/content/full/317/7154/291
HSL537
Krimsky S, Rothenberg LS.
Financial interest and its disclosure in scientific publications.
JAMA 1998 Jul 15;280(3):225-6
http://jama.ama-assn.org/cgi/content/full/280/3/225
HSL506
Strandgaard S.
Conflict of interest in the debate over calcium-channel antagonists.
N Engl J Med 1998 Jun 4;338(23):1697-8
http://content.nejm.org/cgi/content/extract/338/23/1696
HSL528
Meltzer JI.
Conflict of interest in the debate over calcium-channel antagonists.
N Engl J Med 1998 Jun 4;338(23)
http://content.nejm.org/cgi/content/extract/338/23/1696
HSL525
Opie L.
Conflict of interest in the debate over calcium-channel antagonists.
N Engl J Med 1998 Jun 4;338(23):1696-7
http://content.nejm.org/cgi/content/extract/338/23/1696
HSL555
Bero LA.
Disclosure policies for gifts from industry to academic faculty.
JAMA 1998 Apr 1;279(13):1031-2
http://jama.ama-assn.org/cgi/content/full/279/13/1031
HSL548
Stelfox HT, Chua G, O'Rourke K, Detsky AS.
Conflict of interest in the debate over calcium-channel antagonists.
N Engl J Med 1998 Jan 8;338(2):101-6
http://content.nejm.org/cgi/content/abstract/338/2/101
HSL739
Cho M.
Disclosing conflicts of interest.
Lancet 1997 Jul 5;350(9070):72-3
HSL2411
Shuchman M, Wilkes MS.
Medical scientists and health news reporting: a case of miscommunication.
Ann Intern Med 1997 Jun 15;126(12):976-82
http://www.annals.org/cgi/content/full/126/12/976
HSL732
Davidoff F.
Where's the bias?
Ann Intern Med 1997 Jun 15;126(12):986-8
http://www.acponline.org/journals/annals/15jun97/wherbias.htm
HSL676
Smith R.
Conflict of interest in clinical research: opprobium or obsession?
Lancet 1997 Jun 7;349(9066):1703
http://www.thelancet.com/journals/lancet/article/PIIS0140673605626803/fulltext
HSL680
Scheifele DW.
Clinical trials and tribulations: a personal view of interacting with pharmaceutical manufacturers.
Clin Invest Med 1997 Jun;20(3):188-92
Nil
HSL701
Madhavan S, Amonkar MM, Elliott D, Burke K, Gore P.
The gift relationship between pharmaceutical companies and physicians: an exploratory survey of physicians.
J Clin Pharm Ther 1997 Jun;22(3):207-15
Nil
HSL686
Raveendran R, Gitanjali B.
Conflict of interest.
Lancet 1997 Apr 19;349(9059):1173-4
http://www.thelancet.com/search/results?search_searchuri=%2Fsearch%2Fadvanced&search_resulturi=%2Fsearch%2Fresults&search_preview=no&search_reqfirst=1&search_reqcount=20&search_submode=advanced&update_search=no&search_mode=platform&search_cluster=phoenix&search_text1=Raveendran+R+&search_within1=au&search_operator1=and&search_text2=Gitanjali+B&search_within2=au&search_operator2=and&search_text3=&search_within3=all&restrictterm_lancet=lancet&restrictname_lancet=lancet&restricttype_lancet=journal&restrictdesc_lancet=The+Lancet&restrictname_laneur=laneur&restricttype_laneur=journal&restrictdesc_laneur=The+Lancet+Neurology&restrictname_laninf=laninf&restricttype_laninf=journal&restrictdesc_laninf=The+Lancet+Infectious+Diseases&restrictname_lanonc=lanonc&restricttype_lanonc=journal&restrictdesc_lanonc=The+Lancet+Oncology&search_dateradio=combo&search_datecombo=0%3AALL&search_monthstartcombo=1&search_yearstart=1996&search_monthendcombo=1&search_yearend=2005&search_wordsexactly=yes&search_sort=relevance&Submit=Search
HSL715
Horton R.
Conflicts of interest in clinical research: opprobrium or obsession?
Lancet 1997 Apr 19;349(9059):1112-3
HSL673
Stone LR.
Editorials and conflicts of interest.
N Engl J Med 1997 Mar 6;336(10):728
http://content.nejm.org/cgi/search?andorexactfulltext=and&andorexacttitleabs=and&excludeflag=TWEEK_element&search_tab=authors&searchtitle=Authors&hits=20&author1=Stone+LR&sendit=GO&author2=&fulltext=&sortspec=Score+desc+PUBDATE_SORTDATE+desc&fmonth=Aug&fyear=1995&tmonth=Aug&tyear=2005&tocsectionid=Original+Articles&tocsectionid=Special+Reports&tocsectionid=Special+Articles&tocsectionid=Images+in+Clinical+Medicine&tocsectionid=Clinical+Practice&tocsectionid=Case+Records+of+the+Massachusetts+General+Hospital&tocsectionid=Review+ArticlesAORBClinical+PracticeAORBClinical+Implications+of+Basic+ResearchAORBMolecular+Medicine&tocsectionid=Clinical+Problem-Solving&tocsectionid=EditorialsAORBPerspectiveAORBOutlookAORBBehind+the+Research&tocsectionid=Legal+Issues+in+Medicine&tocsectionid=Sounding+BoardAORBClinical+Debate&tocsectionid=Correspondence&tocsectionid=Clinical+Implications+of+Basic+Research&tocsectionid=Book+Reviews&tocsectionid=Health+Policy*AORBQuality+of+Health+Care&tocsectionid=Occasional+Notes
HSL683
Salzman R.
Editorials and conflicts of interest.
N Engl J Med 1997 Mar 6;336(10):728
http://content.nejm.org/cgi/search?andorexactfulltext=and&andorexacttitleabs=and&excludeflag=TWEEK_element&search_tab=authors&searchtitle=Authors&hits=20&author1=Salzman+R&sendit=GO&author2=&fulltext=&sortspec=Score+desc+PUBDATE_SORTDATE+desc&fmonth=Feb&fyear=1997&tmonth=Apr&tyear=1997&tocsectionid=Original+Articles&tocsectionid=Special+Reports&tocsectionid=Special+Articles&tocsectionid=Images+in+Clinical+Medicine&tocsectionid=Clinical+Practice&tocsectionid=Case+Records+of+the+Massachusetts+General+Hospital&tocsectionid=Review+ArticlesAORBClinical+PracticeAORBClinical+Implications+of+Basic+ResearchAORBMolecular+Medicine&tocsectionid=Clinical+Problem-Solving&tocsectionid=EditorialsAORBPerspectiveAORBOutlookAORBBehind+the+Research&tocsectionid=Legal+Issues+in+Medicine&tocsectionid=Sounding+BoardAORBClinical+Debate&tocsectionid=Correspondence&tocsectionid=Clinical+Implications+of+Basic+Research&tocsectionid=Book+Reviews&tocsectionid=Health+Policy*AORBQuality+of+Health+Care&tocsectionid=Occasional+Notes
HSL727
Douglas EF.
Editorials and conflicts of interest.
N Engl J Med 1997 Mar 6;336(10):728
HSL738
Blank NK.
Editorials and conflicts of interest.
N Engl J Med 1997 Mar 6;336(10):728-9
HSL713
Additional statements from the International Committee of Medical Journal Editors.
CMAJ 1997;156(4):571-8
http://www.cma.ca/cmaj/vol-156/issue-4/0571.htm
HSL767
Pritchard MS.
Conflicts of interest: conceptual and normative issues.
Acad Med 1996 Dec;71(12):1305-13
HSL782
Kodish E, Murray T, Whitehouse P.
Conflict of interest in university-industry research relationships: realities, politics, and values.
Acad Med 1996 Dec;71(12):1287-90
HSL753
Tan LB.
The politics of disclosure.
Lancet 1996 Nov 9;348(9037):1314-5
HSL741
Angell M, Kassirer JP.
Editorials and conflicts of interest.
N Engl J Med 1996 Oct 3;335(14):1055-6
HSL772
Manson JE, Faich GA.
Conflicts of interest--editorialists respond.
N Engl J Med 1996 Oct 3;335(14):1064-5
HSL770
Myers MG.
"Drug may have caused huge number of deaths": lessons learned during an encounter with The Fifth Estate.
CMAJ 1996 Sep 15;155(6):772-5
HSL751
[No authors listed].
The politics of disclosure.
Lancet 1996 Sep 7;348(9028):627
HSL764
Rosenberg SA.
Secrecy in medical research.
N Engl J Med 1996 Feb 8;334(6):392-4
HSL5946
Edwards SS, Vinicky JK, Orlowski JP.
Conflicts of interest, conflicting interests, and interesting conflicts, part 2.
J Clin Ethics 1996 Spr 01;7(1):69-76
HSL5947
Orlowski JP, Vinicky JK, Edwards SS.
Conflicts of interest, conflicting interests, and interesting conflicts, Part 3.
J Clin Ethics 1996 Sum 01;7(2):184-6
HSL824
Schubert T.
Risks and benefits of calcium antagonists.
Lancet 1995 Oct 7;346(8980):961
HSL833
Mabin DC.
BMJ should declare its own conflict of interest.
BMJ 1995 Sep 30;311(7009):878-9
http://www.bmj.com/cgi/content/full/311/7009/878/b
HSL838
La Puma J.
Physician rewards for postmarketing surveillance (seeding studies) in the US.
Pharmacoeconomics 1995 Mar;7(3):187-90
HSL6278
Beary JF.
More conflicts of interest: review articles sponsored by the pharmaceutical industry
JAMA 1994;272:1254
HSL6605
Advertising in medical journals
Canadian Medical Association Journal 1994;150:27
HSL6608
Kassirer JP, Angell M.
Conflicts of interest and the Journal’s policies
New England Journal of Medicine 1994;330:504
HSL6722
Leisinger KM.
Professional organizations and healthcare industry support: ethical conflict. Commentary
Cambridge Quarterly of Healthcare Ethics 1994;3:244-247
HSL5151
Sponsored symposia: science or veiled promotion?
WHO Drug Information 1993;7:26-27
HSL5548
La Puma, Stocking CB, Rhoades CM.
Should disclosure of MD remuneration be part of informed consent to research on new drugs?
Clinical Research 1993;41(2):578
HSL6070
Wakefield IR.
Pharmaceutical company sponsorship
New Zealand Medical Journal 1993;106:232
HSL2181
Schwartz TB.
Drug company marketing in the groves of academe.
West J Med 1992 Jun;156(6):660-1
HSL4761
Rennie D, Flanagin A, Glass RM.
Conflicts of interest in the publication of science
JAMA 1991 Jul 10;266(2):266-267
HSL5474
Moore DL.
Recurrent issues in the review of medical research on human subjects.
Albany Law J Sci Technol 1991;1:1-33
HSL2195
Caplan RM.
CME ethics, continued.
Iowa Med 1990 Mar;80(3):135
HSL4502
American Federation for Clinical Research Guidelines for Avoiding Conflict of Interest
Clinical Research 1990;38:239-240
HSL4073
Thompson WG.
The ethics of physician-pharmaceutical company relationships.
CMAJ 1988 Nov 1;139(9):835-6
HSL3926
Weiss GB, Winslade WJ.
Is post-marketing drug follow-up research or advertising?
IRB 1987 Jul-Aug;9(4):10-1
HSL3915
Smith R.
In delicto flagrante
Medical Journal of Australia 1987;146:322-323
HSL3823
Spiro HM.
Mammon and medicine. The rewards of clinical trials
JAMA. 1986 Mar 7;255(9):1174-5 1986 Mar 07;255(9):1174-5
HSL3763
Bearn AG.
Should a drug company employee edit a medical journal?
Lancet 1986;1:974
HSL3768
Burley DM.
Should a drug company employee edit a medical journal?
Lancet 1986;1(801)
HSL3773
Cohen RL.
Drug companies and journal supplements
Lancet 1986;1:1157
HSL3800
Leigh AP.
Should a drug company employee edit a medical journal?
Lancet 1986;1:974
HSL3802
Mac Sheoin T.
Unethical behavior in an ethical industry? Critical coverage of the pharmaceutical industry, 1983-1984
International Journal of Health Services 1986;16:141-162
HSL3826
Stavem P.
Should a drug company employee edit a medical journal?
Lancet 1986;1:684
HSL3828
Turner J.
Antibiotic conference cancelled for second time
Lancet 1986;1:333
HSL3652
Relman AS.
Dealing with conflicts of interest.
N Engl J Med 1985 Sep 19;313(12):749-51
HSL3727
Mintz M.
At any cost: corporate greed, women, and the Dalkon Shield
1985
HSL3685
Altman L.
Dealing with conflicts of interest [4th of 4 letters]
New England Journal of Medicine 1984 Aug 9;311(6):405
HSL3686
Cohen SM.
Dealing with conflicts of interest [1st of 4 letters]
New England Journal of Medicine 1984 Aug 9;311(6):404
HSL3687
Goldstone RA.
Dealing with conflicts of interest [2nd of 4 letters]
New England Journal of Medicine 1984 Aug 9;311(6):404
HSL3688
Nightingale SD, Ansell D, Cohen M, Danel I, Hoffman A, Kiken S, Orris P, Patch O, Ringel P, Sable R, Schiff G, Schiff R, Sherer R, Shansky R, Trainor W, Tully J, Watson C, Kallal C.
Dealing with conflicts of interest [3rd of 4 letters]
New England Journal of Medicine 1984 Aug 9;311(6):404-405
HSL3689
Relman AS.
Dealing with conflicts of interest [Editor's reply]
New England Journal of Medicine 1984 Aug 9;311(6):405
HSL3682
Gouveia WA.
Hospital pharmacy and industry--conflict and collaboration.
Am J Hosp Pharm 1984 Jul;41(7):1391-4
HSL3521
Seaman B, Seaman G.
Women and the crisis in sex hormones
1981
HSL5914
Relman AS.
The new medical-industrial complex.
N Engl J Med 1980 Oct 23;303(17):963-70
HSL3359
Hemminki E, Pesonen T.
An inquiry into associations between leading physicians and the drug industry in Finland.
Soc Sci Med 1977 May;11(8-9):501-6
HSL3299
A critical look at the drug industry: how profits distort medicine
1976:31
HSL3303
Hargraves R.
Introduction
Journal of Drug Issues 1976;6:1-5